Abstract
Cefminox (CMNX, MT-141) is a new injectable cephamycin antibiotic, which was studied for its antibacterial activity, absorption and excretion after administration and clinical efficacy of patients with infections. The following results were obtained.
1. Antibacterial activity
The antibacterial activity of CMNX against 19 clinical isolates consisting of 11 species made the results that its activity against E. coli, P. vulgaris and C. jejuni was superior to CMZ and CEZ.
2. Concentration in serum and urine
CMNX was given intravenously to 3 groups at 20mg/kg by one shot (2 cases), 40mg/kg by one shot (2 cases) and 40mg/kg by 1 hour drip infusion (1 case). The half-lives were between 1.15 to 1.80 hours. We obtained over 70% of its excretion to urine within 6 hours after injection.
3. Clinical efficacy
Clinical evaluation was made on a total of 18 patients with various infections, 11 of whom had underlying diseases. The result was excellent in 1 case, good in 11 cases, fair in 2 cases and poor in 4 cases, and the effective rate was 66.7%.
4. Side effect
Clinical and laboratory abnormal findings related to CMNX were not found.
It is concluded that CMNX seems to be effective and safetive antibiotic in the field of pediatrics.
